Regencell Bioscience (RGC) has had the highest return this year by a US stock in the Biotechnology Industry, returning 471.1%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Regencell Bioscience (RGC) | 2025 | 471.06% |
CervoMed (CRVO) | 2025 | 260% |
DBV Technologies (DBVT) | 2025 | 159.27% |
Chimerix (CMRX) | 2025 | 143.3% |
GRAIL, LLC (GRAL) | 2025 | 108.75% |
Ainos (AIMDW) | 2025 | 107.91% |
Chromocell Therapeutics (CHRO) | 2025 | 102.99% |
Tiziana Life Sciences (TLSA) | 2025 | 97.1% |
Monopar Therapeutics (MNPR) | 2025 | 94.14% |
Nuvectis Pharma (NVCT) | 2025 | 92.48% |
Journey Medical (DERM) | 2025 | 88.64% |
Quantum BioPharma (QNTM) | 2025 | 86.32% |
Inventiva (IVA) | 2025 | 77.63% |
Regulus Therapeutics (RGLS) | 2025 | 72.5% |
2Seventy Bio (TSVT) | 2025 | 67.11% |
Portage Biotech (PRTG) | 2025 | 66.67% |
ABVC BioPharma (ABVC) | 2025 | 65.51% |
INmune Bio (INMB) | 2025 | 65.33% |
Soleno Therapeutics (SLNO) | 2025 | 63.53% |
vTv Therapeutics (VTVT) | 2025 | 62.14% |
AnaptysBio (ANAB) | 2025 | 54.25% |
Protalix Biotherapeutics (PLX) | 2025 | 53.23% |
Theratechnologies (THTX) | 2025 | 53.04% |
Exagen (XGN) | 2025 | 52.58% |
Kalvista Pharmaceuticals (KALV) | 2025 | 51.05% |
